Menstrual blood diagnostics in 2026: what's changing - and what we're tracking
FFHi - Brief: Why menstrual blood diagnostics are entering the mainstream — and what will determine whether they scale
For years, small groups of determined researchers, clinicians and founders have been working to destigmatise and normalise menstrual blood as a source of usable health data.
This month that conversation moved further into the mainstream. Reporting by the BBC on period blood testing as a potential alternative approach to HPV testing within cervical screening marks a moment when menstrual blood diagnostics stopped being framed as a distant idea and started being discussed as a serious public health option.
The significance isn’t that menstrual blood testing will replace cervical screening tomorrow — it won’t. For a start, the specific method discussed is only applicable to people who menstruate regularly, and the research remains early stage.
What is significant however, is that a national public broadcaster is treating menstrual effluent as a legitimate biospecimen that could one day potentially even be used by the NHS, worthy of serious discussion alongside established screening methods.
As we’ve seen with other historically stigmatised areas of health — including menopause — this kind of narrative shift matters. Mainstream awareness, clinical credibility and regulatory interest tend to move together, laying the groundwork for institutional and investor attention.
In the case of menstrual blood, the narrative is beginning to move from “period blood is waste” to “period blood is a potential source of clinical insight.”
And while public awareness may only now be catching up, a growing number of companies and research teams globally are already working with menstrual effluent to detect infection, hormonal signals, fertility markers, metabolic indicators and disease risk.
There are early signals of momentum. Qvin secured FDA clearance in 2024 for its menstrual pad–based diagnostic for diabetes, establishing an important regulatory precedent and sparking a number of media articles and deep dives into menstrual blood. Other teams have secured public funding, clinical pilots or early-stage investment to validate menstrual blood as a diagnostic input.
The question now is not whether menstrual blood can be used for diagnostics — but whether this approach will be adopted at scale, and which use cases and models are most likely to succeed.
Use cases: what menstrual blood diagnostics are — and aren’t — suited for
Menstrual blood is not a universal diagnostic solution. Different conditions vary widely in scientific readiness, regulatory complexity and clinical demand, meaning some applications are progressing faster than others.
Near-term and emerging use cases
These are areas where menstrual blood already shows promise as a practical diagnostic input, often because there is a clear clinical question and an existing comparator.
HPV screening
HPV, as referenced in the BBC article, is currently the most visible use case, in part because it aligns with existing cervical screening frameworks and has established follow-up pathways. If any use case will be the one to help menstrual blood diagnostics ‘break through’ it will be this one.Heavy menstrual bleeding (HMB)
Measuring blood loss or related markers could help quantify a condition that is widely under-diagnosed and often dismissed as subjective. In this use case, the biomarkers within the period blood aren’t the focus, but the analysis of the volume of the blood itself.Endometriosis screening and triage
While not a replacement for definitive diagnosis, menstrual blood may support earlier screening or risk stratification, helping to reduce diagnostic delays. Considering current diagnosis times stand at 8-10 years, this could be the use case with one of the most significant impacts.
Medium- to longer-term use cases in development
Beyond screening, some teams are exploring menstrual blood as a window into broader aspects of health. These applications are scientifically compelling, but may face higher validation and regulatory hurdles.
Hormonal health and cycle dynamics, particularly through longitudinal monitoring
Metabolic and inflammatory markers, where clinical relevance is still being established.
Sexual and reproductive health, including infections beyond HPV and fertility-related markers.
Cancer detection beyond HPV, which remains exploratory and long-term.
Not all use cases will mature at the same pace, and clarity of clinical purpose will be critical.
Companies and platforms we’re tracking
This is a non-exhaustive list (in no particular order), but reflects the range of approaches shaping progress in menstrual blood diagnostics today. Notably, it’s quite a global list, with significant representation outside of the U.S:
